1. Home
  2. DMAC vs FLXS Comparison

DMAC vs FLXS Comparison

Compare DMAC & FLXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

N/A

Current Price

$7.05

Market Cap

342.7M

Sector

Health Care

ML Signal

N/A

Logo Flexsteel Industries Inc.

FLXS

Flexsteel Industries Inc.

N/A

Current Price

$73.58

Market Cap

290.6M

ML Signal

N/A

Company Overview

Basic Information
Metric
DMAC
FLXS
Founded
2000
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Home Furnishings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
342.7M
290.6M
IPO Year
2018
1995

Fundamental Metrics

Financial Performance
Metric
DMAC
FLXS
Price
$7.05
$73.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$15.50
$54.00
AVG Volume (30 Days)
250.8K
46.3K
Earning Date
05-13-2026
04-20-2026
Dividend Yield
N/A
1.41%
EPS Growth
N/A
N/A
EPS
N/A
3.63
Revenue
$500,000.00
$441,073,000.00
Revenue This Year
N/A
$4.51
Revenue Next Year
N/A
$4.89
P/E Ratio
N/A
$20.07
Revenue Growth
N/A
N/A
52 Week Low
$4.01
$32.65
52 Week High
$10.42
$77.19

Technical Indicators

Market Signals
Indicator
DMAC
FLXS
Relative Strength Index (RSI) 50.25 64.13
Support Level $5.51 $68.02
Resistance Level $7.06 $77.19
Average True Range (ATR) 0.53 3.21
MACD -0.07 -0.41
Stochastic Oscillator 24.15 50.78

Price Performance

Historical Comparison
DMAC
FLXS

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About FLXS Flexsteel Industries Inc.

Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.

Share on Social Networks: